Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab and Nimotuzumab in Locally Advanced ESCC (NCRCN)
NCT05355168Phase 2Completed
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Nov 2021
- Primary completion
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab, nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of USTC. Started Nov 2021; status: completed.
02
Drugs
camrelizumabnimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT05355168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05355168.